After extensive foundational research, SFM Corporation independently developed the Android app “FLD HbA1c,” which was launched in seven countries across Southeast and Southwest Asia on October 22, 2025. Subsequently, it was released in five countries within the Asia-Oceania region on November 3, 2025, and in four countries within the Asia-Central America region on November 16, 2025. As a result, the app has been expanded to a total of 17 countries, including Japan.
We are pleased to announce the expansion of release countries to the South American region.
The targeted country is as follows:
- Brazil
The installation can be done via the SFM App Store.
SFM App Store
Going forward, we plan to further increase the number of countries where the app is released, and will provide updates in press releases as new countries are added.
Currently, only a subscription model is available for the payment scheme. However, we plan to introduce non-automatic billing methods, such as a prepaid system. Details regarding these changes will be shared in a press release once finalized.
*Important Notice: The “FLD HbA1c” is not a medical or diagnostic tool. This app is Wellness App. The measurements provided by this mobile application are intended for informational purposes and are aimed at promoting general health. The assessment metrics are not intended for medical use, including self-diagnosis or consultation with a physician. Please consult a healthcare professional when seeking treatment or a diagnosis. Please note that our products are not medical devices as defined by the relevant pharmaceutical laws. There are also restrictions on compatible devices. Please check if your device is supported and ensure you read the applicable terms of use and privacy policy before using our services.